Bacterial endospore-based biological control agents for dipteran insect pests

Overview

This research-stage solution explores the use of bacterial endospores as biological control agents against dipteran insect pests. Two novel bacterial strains — Lysinibacillus fusiformis and Paenibacillus taichungensis — were isolated from diseased Drosophila simulans laboratory cultures and shown to produce endospores that are highly toxic when ingested by larvae. Preliminary data indicates up to 100% larval or pupal mortality in D. melanogaster and D. simulans, suggesting strong potential as targeted, orally delivered biocontrol agents. The researchers aim to extend this work to Drosophila suzukii (spotted-wing drosophila), a major invasive fruit crop pest in North America, as well as to mosquito larvae, broadening the agricultural and public health applications.

Technical specifications

Key features:

• Two characterized novel bacterial strains capable of producing endospores under defined in vitro conditions on both solid and liquid media
• Demonstrated high oral toxicity: L. fusiformis endospores cause 100% larval death, while P. taichungensis endospores cause 100% pupal death in Drosophila species
• Both strains exhibit biofilm formation in vitro, a potential virulence mechanism that may enhance persistence and pathogenicity in target hosts
• Sporulation protocols established in broth format, enabling scalable production and standardized multiwell-plate bioassays for lethal dose quantification
• Planned whole-genome sequencing to identify genetic biomarkers linked to toxin production and biofilm formation

Technology readiness level

The technology is at an early research and validation stage (TRL 3–4). Efficient in vitro sporulation conditions have been established, and qualitative oral infection data in Drosophila has confirmed high mortality. Future work includes quantitative lethal dose determination in sporulation broth, host-range testing against D. suzukii and mosquito larvae, and genomic characterization of virulence factors. The solution is not yet commercially available and requires further validation before deployment as a registered biocontrol product.